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The inhibition of serine proteinases by both synthetic and natural inhibitors has been widely studied. Eglin c is a small thermostable protein isolated 
from the leech, Hirudo medicinalis. Eghn c is a potent serine proteinase inhibitor. The three-dimensional structure of native eghn and of its complexes 
with a number of proteinases are known. We here describe the crystal structure of hydrolysed eghn not bound to a proteinase. The body of the 
eghn has a conformation remarkably similar to that in the known complexes with proteinases. However, the peptide chain has been cut at the 
‘scissile’ bond between residues 45 and 46, presumed to result from the presence of subtilisin DY in the crystallisation sample. The residues usually 
making up the inhibiting loop of eghn take up a quite different conformation in the nicked inhibitor leading to stabilising contacts between 
neighbouring molecules in the crystal. The structure was solved by molecular eplacement techniques and refined to a final R-factor of 14.5%. 
Eglin c; Serine proteinase inhibitor: Hydrolysed reactive loop; Crystal structure 
1. INTRODUCTION 
Serine proteinases have an active site involving three 
catalytic residues: serine, histidine and aspartate. They 
fall into two main families: the trypsin, chymotrypsin 
and elastase group, and the subtilisin-like enzymes. The 
enzymes within each individual family have diverged 
from a common ancestor, but the two families show no 
similarity in sequence or three-dimensional structure 
and appear to have converged on the same solution for 
proteinase activity [ 11. The serine proteinases have been 
extensively studied by a variety of biochemical and ge- 
netic techniques and their mechanism and specificity is 
well understood [2,3]. In addition the three-dimensional 
structures have been determined for several enzymes 
from both families, as well as their complexes with syn- 
thetic and naturally occurring protein inhibitors and for 
many site-directed mutants [4-71. 
In spite of the difference in protein fold for the two 
families their binding sites show certain similarities. In 
both cases there are clefts on the surface of the enzyme 
with defined sites for a number of amino acid residues 
on each side of the scissile bond of the substrate [8]. The 
nature of these sites confers a different specificity on the 
various enzymes. Thus trypsin hydrolyses peptides on 
the carboxy side of arginine and lysine, chymotrypsin 
prefers large aromatic residues, and elastase small side 
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chains. In contrast subtilisins are relatively broad in 
their specificity [l]. 
Eglin c is a naturally occurring polypeptide from the 
leech Hirudo medicinalis [9]. It powerfully inhibits both 
chymotrypsin [lo] and subtilisin [4,11], and in addition 
the leukocyte proteinases elastase and cathepsin G [12], 
through the formation of 1:l complexes. It has thus 
attracted particular attention as a possible therapeutic 
agent against various pathogenic elastic tissue agents, 
blood clotting disorders and inflammatory processes. 
Native eglin contains 70 amino acids. The 6 or 7 N- 
terminal residues of native eglin appear to be cleaved off 
by many proteinases. The three-dimensional crystal 
structures of several complexes of eglin with members 
of both families have been determined. Only complexes 
with subtilisins are discussed below. Most of the eglin 
molecule makes up a central rigid body, with a hydro- 
phobic core. The structure of this body is essentially the 
same in all complexes tudied. The inhibitory loop, res- 
idues 40-50, points away from the surface of this body 
and mimics the substrate when bound to the active site 
of the proteinases. The peptide bond between residues 
45 and 46 lies in the position of the scissile bond of the 
substrate. The body and the loop of eglin take up differ- 
ent relative conformations in the various complexes 
studied, the loop bending about hinges at each end. 
The solution structure of eglin c was determined by 
NMR techniques [13]. It was attempted unsuccessfully 
for many years to crystallize eglin on its own [4], but 
only recently the wild-type structure of eglin was re- 
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Fig. 1. Stereo view of the Ca positions of intact eglin taken from the mesentericopeptidase complex (thin lines) superimposed on the cleaved inhibitor 
from the present study (thick lines). Residues 39 to 45 take up a completely different conformation in the nicked eglin, and the N-terminal residue 
moves slightly. The body of the molecule retains the same conformation as in the complex. 
ported [14]. Eglin has been used to form complexes of 
proteinases to avoid autolysis of the enzymes. We have 
crystallized complexes with both thermitase and mesen- 
tericopeptidase and determined their structures [15,161. 
Other groups have solved the structure of subtilisin 
Carlsberg [4,1 I] and thermitase [17] with eglin. More 
recently we tried to co-crystallize eglin with subtilisin 
DY, which differs by only 31 amino acids from 
Carslberg, out of 270 [18]. 
2. MATERIALS AND METHODS 
Crystals of eglin c were grown at 16°C by hangmg drop vapour 
diffusion [19] under the conditions described for the complex between 
eglin and subtilisin Carlsberg [4]. Eglin c (10 mg/ml) in 0.02 M acetic 
acid was mixed at a ratio of 1.2:1.5 with subtilisin DY (around 8 
mg/ml) in 0.1 M sodium acetate, pH 6.0. Crystals were obtained in a 
small percentage of the experiments. 
The space group of the crystals was P43 with umt cell parameters 
of a and b = 42.0 A and c = 35.9 A. As judged by this unit cell 
surprisingly the crystals appeared to contain no proteinase. This is a 
classic example of serendipity in crystallisation conditions; one would 
not imagine that addition of subtilisin DY would be necessary to 
obtain crystals of eglin. The asymmetric unit finally contains one 
molecule of hydrolysed eglin. The packing density parameter V,,, was 
calculated to be 2.3 A’IDalton [20]. A single crystal mounted in a glass 
capillary was used to collect data on a conventional sealed tybe X-ray 
source with MoK, radiation and a graphite monochromator. A MAR 
imaging plate detector was used to collect data up to 2.0 A resolution. 
The reduced data set contains 4,131 reflections and shows a complete- 
ness of 982, with 93% of those measured having intensities greater 
than three standard deviations. The Rmerge defined as 
R(I) = X lZ-<I> 1x1 is 6.0%. 
The structure solution was achieved by molecular replacement with 
an eglin model from the mesentericopeptidase complex and was not 
straightforward. It was eventually achieved using a new rotation and 
translation program AMORE [21]. After adjustment of the position 
as a single rigid body, the model was initially refined using an auto- 
matic refinement procedure developed in EMBL Hamburg [22]. After 
this step the rebuilding of the model was performed by inspecting 
2F,-F, synthesis and F,-F, difference Fourier synthesis, and ‘omit’ 
maps where particular parts around the N terminus and in the region 
of the hydrolysed bond were omitted from phase calculation. All 
graphics work was carried out using the program FRODO [23] on an 
Evans and Sutherland PS 300 system. Finally the model was refined 
186 
using stereochemically restrained least squares minimisation [24] to an 
R factor of 14.5%. The mean temperature factor for all main chain 
atoms was 11.1 A* and for all side chain atoms 15.5 Az. The r.m.s. 
errors in bond lengths compared to the target values was 0.024 A. The 
torsion angles w of the peptide planes have mean deviation of 2.8O with 
respect o the ideal value of 180”. 
3. RESULTS AND DISCUSSION 
Eglin c has no disulfide bonds but is even then very 
stable against denaturation by heat. The structure con- 
sists of a well defined rigid core, with an cl-helix on one 
side, a four stranded B-sheet and a binding loop with 
high mobility. Eglin c is a member of the potato inhib- 
itor family [25] where the homologous structure of the 
proteinase inhibitor CI-2 from barley seeds has been 
determined in complex with proteinases by X-ray crys- 
tallography [26]. The structure of eglin in the crystal is 
shown in Fig. I, overlapped with intact eglin as in the 
mesentericopeptidase complex. A most striking feature 
is that the inhibitor has been cleaved at the scissile bond: 
‘This was the most unkindest cut of all’ 1271. The body 
of eglin maintains the same structure as in the complex, 
with an r.m.s. difference in Ca positions of only 0.3 A. 
This indicates high rigidity and high stability for the 
core of eglin: its structure is maintained even when the 
loop has been cleaved in the presence of proteinase. 
Residues 40 to 45 on the N-terminal side of the scissile 
bond have a well defined position in the crystal with 
clear electron density, Fig. 2, quite different from that 
in the intact loop in the complex. Residues 49 and 50 
also take up well defined new positions. There is how- 
ever no density for residues 4648 and it is not clear 
whether these are disordered or have been cleaved from 
the rest of the peptide chain. Also there is no electron 
density for the first 6 residues at the N terminus as 
observed in other complex structures. This could be due 
to local disorder or to specific hydrolysis. In the recently 
reported free eglin c structure the N terminus was 
clearly visible in the electron density. Residues 40 to 45 
point away from the body of eglin in the present struc- 
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Fig. 2. Stereoview of the (2F,-F,) electron density contoured at the 1.3~ level around residues 43 to 45 in the nicked eglin structure. These residues 
have good electron density and take up a well defined conformation packed between two neighbouring molecules in the crystal lattice. 
ture, in an extended conformation. They lie close to the 
4-fold screw axis and the side chains make extensive 
contacts with each other and with the cores of neigh- 
bouring eglin molecules in the crystal lattice, Fig. 3. 
This may well confer stability on the particular confor- 
mation and thus facilitate crystallization. It is not clear 
why subtilisin DY appears to cleave eglin under condi- 
tions where highly homologous subtilisin Carlsberg and 
Fig. 3. Stereo picture of the Car positions of the four nicked eglin molecules in the unit cell viewed down the Cfold axis. The extended arms, residues 
39 to 45, pack around the axis against symmetry related eghn molecules. 
187 
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also other proteinases from the subtilisin family do not. 
Experiments are planned to address this question. 
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